Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - alteplase - powder and solvent for solution for injection/infusion - alteplase 20 mg/vial - enzymes - acute myocardial infarction :actilyse is indicated for use in the management of acute myocardial infraction (ami) in adults for the lysis of thrombi obstructing coronary arteries, the reduction of infract size, improvement of ventricular function, the reduction of the incidence of congestive heart failure and the reduction of mortality associated with ami. treatment should be initiated as soon as possible after the onset of ami symptoms.acute massive pulmonary embolism with hemodynamic deprivation:actylise is indicated in the management of acute massive pulmonary embolism (pe) in adults:- for the lysis of acute pulmonary emboli, defined as obstruction of blood flow to a lobe or multiple segments of the lung, and- for the lysis of pulmonary emboli accompanied by unstable hemodynamics e.g. failure to maintain blood pressure without supportive measures. the diagnosis should be confirmed by objective means, such as pulmonary angiography or noninvasive procedures such as lung scanning. for fibrinolytic treatment of acute ischaemic stroke.treatment must be started as early as possible within 4.5 hours after onset of stroke symptoms and after exclusion of intracranial haemorrhage by appropriate imaging techniques (e.g. cranial computerised tomography or other diagnostic imaging method sensitive for the presence of haemorrhage). the treatment effect is time-dependent; therefore earlier treatment increases the probability of a favourable outcome. this treatment is restricted to a prescription by a specialist in neurology.

Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim limited - alteplase - pdr+solv for soln for inf/inj - 2 milligram - alteplase

Canada - English - Health Canada

hoffmann-la roche limited - alteplase - powder for solution - 2mg - alteplase 2mg - thrombolytic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 10 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; calcium hydrogen phosphate dihydrate; iron oxide red; mannitol; maize starch - hypertension: for treatment of hypertension, lisinopril may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure: for treatment of heart failure, it is recommended that lisinopril be administered together with a diuretic. acute myocardial infarction: for treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg, lisinopril may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - lisinopril dihydrate, quantity: 10.89 mg (equivalent: lisinopril, qty 10 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; iron oxide red; colloidal anhydrous silica; mannitol; maize starch; calcium hydrogen phosphate dihydrate; pregelatinised maize starch - hypertension. lisinopril generic health tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure lisinopril generic health tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that lisinopril generic health tablets be administered together with a diuretic. acute myocardial infarction: lisinopril generic health tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100mmhg. lisinopril may be initiated within 24 hours of an acute myocardial infarction.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - phenindione - oral tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

advanz pharma - phenindione - oral tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - phenindione - oral tablet - 10mg

Australia - English - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - lisinopril, quantity: 10 mg - tablet, uncoated - excipient ingredients: mannitol; maize starch; iron oxide red; calcium hydrogen phosphate dihydrate; magnesium stearate; pregelatinised maize starch - hypertension: zestril is indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure: zestril is also indicated in the treatment of heart failure. in such patients, it is recommended that zestril be administered together with a diuretic. acute myocardial infarction: zestril is indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100mg hg. zestril may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - caplacizumab, quantity: 10 mg - injection, powder for - excipient ingredients: - cablivi is indicated for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (attp), in conjunction with plasma exchange and immunosuppression.